Fig. 5.

Stratification of patients based on FOXP3⁺RORγt⁺ T cells and CD8⁺ T cells predicts prognosis and therapeutic responsiveness in gastric cancer. a In order to stratify gastric cancer patients more precisely, we combined and co-evaluated the infiltration of Foxp3⁺RORγt⁺ T cells and CD8⁺ T cells in gastric cancer. Based on the combined evaluation system, we divided patients into high risk group (Foxp3⁺RORγt⁺ T cells high and CD8⁺ T cells low), intermediate risk group (Foxp3⁺RORγt⁺ T cells high and CD8⁺ T cells high), and low risk group (Foxp3⁺RORγt⁺ T cells low). The three risk groups showed distinct survival outcomes (P = 0.0005). b–e The three risk groups also showed distinct therapeutic responsiveness to ACT. The patients of lower risk group could significantly benefit from ACT (HR: 0.3659, 95% CI: 0.2219–0.6033, P < 0.0001), while either high risk group or intermediate risk group merely had a trend towards improved survival after receiving ACT (HR: 0.5846, 95% CI: 0.2795–1.223, P = 0.0873 and 1.063, 95% CI: 0.5428–2.082, P = 0.8586)